Dr. O'Malley on Toxicity Profiles of PARP Inhibitors in Ovarian Cancer

Video

In Partnership With:

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

According to O’Malley, veliparib, niraparib (Zejula), olaparib (Lynparza), and rucaparib (Rubraca) have similar toxicities. All 4 PARP inhibitors are associated with gastrointestinal adverse events (AEs) such as nausea and constitutional AEs such as fatigue, explains O’Malley.

Notably, veliparib seems to have a lower incidence of hematologic toxicity in combination with chemotherapy, says O’Malley. Conversely, niraparib has a greater risk of hematologic AEs such as thrombocytopenia. However, an analysis from the phase III ENGOT-OV16/NOVA trial showed that baseline body weight and platelet counts could be used as early predictors for future AE-related dose modifications for niraparib, helping mitigate this risk.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,